10.51  0.01 (0.1%)		04-26 16:00
Open: 10.47 High: 10.75 Volume: 19,945		Pre. Close: 10.5 Low: 10.4 Market Cap: 547(M)

Short term
Mid term
Targets	6-month :	13.42	1-year :	14.31
Resists	First :	11.49	Second :	12.26
Pivot price	11.09
Supports	First :	10.26	Second :	8.53
MAs	MA(5) :	11.02	MA(20) :	11.08
	MA(100) :	8.15	MA(250) :	9.43
MACD	MACD :	0.2	Signal :	0.3
%K %D	K(14,3) :	17.4	D(3) :	33.1
RSI	RSI(14): 46.8
52-week	High :	14.64	Low :	5.05

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ GHRS ] has closed above bottom band by 4.9%. Bollinger Bands are 25% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	10.76 - 10.82	10.82 - 10.88
Low:	10.25 - 10.32	10.32 - 10.4
Close:	10.39 - 10.51	10.51 - 10.61

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Mon, 22 Apr 2024
GH Research (NASDAQ:GHRS) Shares Up 6.8% - MarketBeat

Wed, 17 Apr 2024
GH Research (NASDAQ:GHRS) Shares Down 3.1% - MarketBeat

Mon, 15 Apr 2024
GH Research (NASDAQ:GHRS) Shares Up 2.6% - MarketBeat

Fri, 12 Apr 2024
GH Research (NASDAQ:GHRS) Stock Price Down 0.5% - MarketBeat

Fri, 01 Mar 2024
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Thu, 29 Feb 2024
GH Research pushes forward with DMT trials, drug approvals - Green Market Report

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	52 (M)
Shares Float	8 (M)
Held by Insiders	40.3 (%)
Held by Institutions	60 (%)
Shares Short	1,310 (K)
Shares Short P.Month	1,280 (K)

EPS	-0.69
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.21
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-10.8 %
Return on Equity (ttm)	-15.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.8
Qtrly Earnings Growth	0 %
Operating Cash Flow	-33 (M)
Levered Free Cash Flow	-22 (M)

PE Ratio	-15.46
PEG Ratio	0
Price to Book value	2.49
Price to Sales	0
Price to Cash Flow	-16.41

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.